| Source: HalifaxProj(inhibit) |
| Type: |
| Akt1 is involved in cellular survival pathways, by inhibiting apoptotic processes; Akt2 is an important signaling molecule in the insulin signaling pathway. It is required to induce glucose transport. Inhibitors: -Curcumin: downregulate AKT phosphorylation and signaling. -Resveratrol -Quercetin: inhibit the PI3K/AKT pathway. -Epigallocatechin Gallate (EGCG) -Luteolin and Apigenin: inhibit AKT phosphorylation |
| 8414- | Lyco, | Exploring the Therapeutic Potential of Lycopene: Mechanisms, Biological Activities, and Health Benefits |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 8407- | Lyco, | Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines |
| - | in-vitro, | Pca, | LNCaP |
| 4800- | Lyco, | Recent insights on pharmacological potential of lycopene and its nanoformulations: an emerging paradigm towards improvement of human health |
| - | Review, | Var, | NA |
| 4786- | Lyco, | Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines |
| - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | SkBr3 |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4795- | Lyco, | Updates on the Anticancer Profile of Lycopene and its Probable Mechanism against Breast and Gynecological Cancer |
| - | Review, | BC, | NA |
| 1126- | Lyco, | Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway |
| - | vitro+vivo, | Oral, | NA |
| 1089- | MAG, | Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways |
| - | in-vitro, | AML, | RAW264.7 |
| 972- | MAG, | Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells |
| - | vitro+vivo, | Bladder, | T24/HTB-9 |
| 5252- | MAG, | Insights on the Multifunctional Activities of Magnolol |
| - | Review, | Var, | NA |
| 8525- | MAG, | Mechanisms for the magnolol-induced cell death of CGTH W-2 thyroid carcinoma cells |
| - | in-vitro, | Thyroid, | NA |
| 8524- | MAG, | Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | CRC, | HCT116 |
| 8521- | MAG, | Magnolol induces apoptosis via caspase-independent pathways in non-small cell lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H520 | - | in-vitro, | Lung, | NCI-H441 |
| 8505- | MAG, | Role of magnolol in gastrointestinal cancers: Recent trends and future perspectives |
| - | Review, | GC, | NA |
| 8516- | MAG, | Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma |
| - | in-vitro, | Melanoma, | NA |
| 4533- | MAG, | Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways |
| - | in-vitro, | GC, | SGC-7901 |
| 4514- | MAG, | Magnolol and its semi-synthetic derivatives: a comprehensive review of anti-cancer mechanisms, pharmacokinetics, and future therapeutic potential |
| - | Review, | Var, | NA |
| 4515- | MAG, | Magnolol as a Potential Anticancer Agent: A Proposed Mechanistic Insight |
| - | Review, | Var, | NA |
| 4535- | MAG, | 5-FU, | Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways |
| - | in-vitro, | Cerv, | NA |
| 4528- | MAG, | Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update |
| - | Review, | Nor, | NA |
| 4519- | MAG, | Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer |
| - | Review, | Var, | NA |
| 8564- | Matr, | Matrine inhibits proliferation and promotes autophagy and apoptosis in non-small cell lung cancer cells by deactivating PI3K/AKT/mTOR pathway |
| - | in-vitro, | Lung, | A549 |
| 8565- | Matr, | Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathway |
| - | in-vitro, | AML, | THP1 |
| 8533- | Matr, | Matrine induces the apoptosis of lung cancer cells through downregulation of inhibitor of apoptosis proteins and the Akt signaling pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | 95D |
| 8542- | Matr, | Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling |
| - | vitro+vivo, | Lung, | A549 |
| 8538- | Matr, | Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling |
| - | in-vitro, | BC, | MDA-MB-231 | - | ex-vivo, | BC, | MDA-MB-231 |
| 8534- | Matr, | Matrine induces apoptosis and autophagy in human lung adenocarcinoma cells via upregulation of Cavin3 and suppression of PI3K/AKT pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | MRC-5 |
| 8530- | Matr, | Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transition |
| - | in-vitro, | HCC, | NA |
| 8526- | Matr, | A Systematic Review of the Pharmacology, Toxicology and Pharmacokinetics of Matrine |
| - | Review, | Nor, | NA |
| 8544- | Matr, | Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential |
| - | Review, | BC, | NA |
| 8558- | Matr, | Matrine exerts anti‑breast cancer activity by mediating apoptosis and protective autophagy via the AKT/mTOR pathway in MCF‑7 cells |
| - | in-vitro, | BC, | MCF7 |
| 8555- | Matr, | Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review |
| - | Review, | Var, | NA |
| 8553- | Matr, | Research progress on the pharmacological effects of matrine |
| - | Review, | Nor, | NA |
| 8547- | Matr, | Matrine in cancer therapy: antitumor mechanisms and nano-delivery strategies |
| - | Review, | Var, | NA |
| 8543- | Matr, | Mechanism of matrine inhibiting retinoblastoma cell growth by downregulating NR1D2 to regulate phosphorylation of the PI3K/AKT signaling pathway |
| - | in-vitro, | RPE/RB, | Y79 |
| 7824- | MBS, | IVT, | VT, | Neuroprotective Potential of Mung Bean (Vigna radiata L.) Polyphenols in Alzheimer's Disease: A Review |
| - | Review, | AD, | NA | - | Review, | Stroke, | NA | - | Review, | Park, | NA |
| 8644- | MBZ, | The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer |
| - | vitro+vivo, | CRC, | HT-29 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 |
| 8819- | MCP, | PacT, | Pectasol‐C Modified Citrus Pectin targets Galectin‐3‐induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids |
| - | in-vitro, | Ovarian, | SKOV3 |
| 8822- | MCP, | Modified citrus pectin inhibited bladder tumor growth through downregulation of galectin-3 |
| - | vitro+vivo, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 |
| 8620- | MCT, | Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context—A Concise Review |
| - | Review, | Nor, | NA |
| 2643- | MCT, | Medium Chain Triglycerides enhances exercise endurance through the increased mitochondrial biogenesis and metabolism |
| - | Review, | Nor, | NA |
| 8756- | MeSA, | THE MAIN CYTOTOXIC EFFECTS OF METHYLSELENINIC ACID ON VARIOUS CANCER CELLS |
| - | Review, | Var, | NA |
| 8749- | MeSA, | etoposide, | Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo |
| - | in-vivo, | Pca, | NA |
| 8748- | MeSA, | Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 8743- | MeSA, | PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 |
| 8742- | MeSA, | Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells |
| - | in-vitro, | Pca, | DU145 |
| 8763- | MeSA, | Methylseleninic Acid Provided at Nutritional Selenium Levels Inhibits Angiogenesis by Down-regulating Integrin β3 Signaling |
| - | vitro+vivo, | Nor, | HUVECs |
| 8711- | MET, | https://pubmed.ncbi.nlm.nih.gov/42725610/ |
| - | Review, | Var, | NA |
| 2375- | MET, | Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling |
| - | in-vitro, | GC, | SGC-7901 |
| 2243- | MF, | Pulsed electromagnetic fields increase osteogenetic commitment of MSCs via the mTOR pathway in TNF-α mediated inflammatory conditions: an in-vitro study |
| - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:4 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid